News articles about Amgen (NASDAQ:AMGN) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amgen earned a coverage optimism score of 0.18 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 46.4828223664665 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- June 2019 Options Now Available For Amgen (AMGN) (nasdaq.com)
- See what the IHS Markit Score report has to say about Amgen Inc. (finance.yahoo.com)
- 5 Things Amgen's CEO Just Said That Investors Need to Know (finance.yahoo.com)
- How Incyte’s Jakafi Performed in 3Q17 (finance.yahoo.com)
- Belgium’s Biocartis, Amgen In Deal To Develop Idylla CDx Biomarker Tests (markets.businessinsider.com)
Several equities analysts have recently weighed in on the company. Royal Bank of Canada assumed coverage on Amgen in a report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price target on the stock. Bank of America increased their price target on Amgen to $210.00 and gave the company a “buy” rating in a report on Thursday, October 5th. Oppenheimer reissued a “buy” rating and set a $203.00 price target on shares of Amgen in a report on Friday, October 6th. Mizuho reissued a “buy” rating and set a $198.00 price target on shares of Amgen in a report on Friday, October 6th. Finally, Morgan Stanley reissued an “overweight” rating and set a $196.00 price target (up from $189.00) on shares of Amgen in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have issued a buy rating to the stock. Amgen has an average rating of “Hold” and a consensus price target of $190.15.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same quarter in the prior year, the business posted $3.02 EPS. Amgen’s revenue for the quarter was down .7% compared to the same quarter last year. equities analysts anticipate that Amgen will post 12.71 earnings per share for the current fiscal year.
Amgen announced that its Board of Directors has initiated a share buyback program on Wednesday, October 25th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its stock is undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be paid a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $1.15. Amgen’s dividend payout ratio is presently 41.55%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total transaction of $269,665.75. Following the completion of the transaction, the executive vice president now owns 56,106 shares of the company’s stock, valued at approximately $9,921,223.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders sold a total of 7,050 shares of company stock valued at $1,225,765 in the last quarter. 0.19% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This report was published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.themarketsdaily.com/2018/01/11/amgen-amgn-earning-somewhat-positive-media-coverage-analysis-finds.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.